Where Next-Generation Metabolic Therapies Begin
Diasome is advancing a new class of medicines that restore the body’s natural physiology. Our HDV™ platform enables cell specific delivery, offering scalable improvements in how drugs are developed and how care is provided.
.avif)
A team anchored by deep cardiometabolic expertise
Since its founding in 2012, Diasome has been a scientifically driven organization that focuses on translating novel therapeutic insights to develop innovative medicine for diabetes, obesity, and metabolic diseases.
Our core technology platform harnesses endogenous mechanisms to resolve metabolic dysregulation across a broad range of diseases.
.avif)
"When we deliver medicines to the right metabolic pathways, we unlock their full potential—improving both how they work and who they can help."
Robert Geho, MBA
Co-Founder, Chief Executive Officer
Meet our team
Robert Geho, MBA
CO-FOUNDER, CHIEF EXECUTIVE OFFICER
W. Blair Geho, MD, PhD
CO-FOUNDER, CHIEF SCIENTIFIC OFFICER
Paul Strumph, MD
chief medical officer (Interim)
Caroline El Sanadi, PhD
Vice President of PHARMACEUTICAL SCIENCES & TECHNOLOLGY
J. Lincoln Chapin
Vice President of Clinical Operations
Board of Directors
Robert Geho, MBA
CO-FOUNDER, CHIEF EXECUTIVE OFFICER
W. Blair Geho, MD, PhD
CO-FOUNDER, CHIEF SCIENTIFIC OFFICER
Frank McCaney
INDEPENDENT DIRECTOR
Thomas McDonald
Cosme Ordonez, MD
Peter Tollman, PhD
BOARD CHAIRMAN
Eric Edidin
OBSERVER
Daniel Flicker, PhD
OBSERVER
Josh Hexter
OBSERVER
.jpg)